Everyday Vasculitis (or what questions do we get asked most!) Lucy Smyth Renal Consultant

Size: px
Start display at page:

Download "Everyday Vasculitis (or what questions do we get asked most!) Lucy Smyth Renal Consultant"

Transcription

1 Everyday Vasculitis (or what questions do we get asked most!) Lucy Smyth Renal Consultant

2 What is it? Why have I got it? How can we treat it? Why do I feel like I do? What do the blood tests mean? Will it go away? What can I do to help myself?

3 What is it? Vascul = blood vessel itis = inflammation Can affect small, medium and large vessels Varying patterns of disease according to the vessels affected

4

5 Kidneys Glomerulonephritis = inflammation of the filters Blood and protein in urine Rapid deterioration of function High blood pressure Eyes Inflammation Nerve damage General Night sweats Weight loss Tiredness Rash Joints Synovitis = inflammation of joint lining Lungs Pulmonary haemorrage = bleeding Infiltrates = inflammation Granulomas = inflammatory lumps Nerves Weakness Loss sensation Confusion ENT Deafness Sinusitis Nosebleeds Nasal crusting Gut Bleeding Pancreatitis

6 Why have I got it? The way your immune system is made up Genetic, but not directly inherited What your immune system has come across Environment The way your immune system has reacted to it Often a trigger, eg infection

7 ANCA (anti neutrophil cytoplasmic antibodies) Antibodies that bind to certain white blood cells Cause the white blood cells to release toxic substances Causes inflammation of the blood vessels

8 ANCA (anti neutrophil cytoplasmic antibodies) P-ANCA C-ANCA

9 How can we treat it? Hit it hard Induction treatment Keep it under control Maintenance treatment Slowly try to wean down/off According to disease activity P-ANCA min 2-3 years, c-anca min 5 years

10 How can we treat it? Cyclo Steroids AZA

11 Cyclophosphamide Induction The oldest, and not yet surpassed Much shorter courses now: 3 months = minimal toxicity Knocks out the antibody producing B cells Careful monitoring: weekly bloods Oral or IV pulses Risks Infection, low WBC, hair thinning, infertility, malignancy

12 Azathioprine Maintenance Oldest and not yet surpassed Blocks turnover of inflammatory cells Need to check TPMT level Oral, once daily Monthly bloods Risks Infection, nausea, liver inflammation, low WBC, skin malignancy

13 Steroids Induction / maintenance Important for early control of inflammation No one has yet found a way of avoiding them Trials being proposed to minimise dosing regimes / avoid Risks Infection, bruising, diabetes, osteoporosis, thinned skin

14 How can we treat it? Plasma Exchange Cyclo Steroids Rituximab AZA

15 Plasma Exchange At start of induction treatment Current indications: Creatinine >500 Pulmonary haemorrhage Removes circulating ANCA Similar to dialysis; daily sessions for a week Risks Infection, bleeding, allergic reaction

16 Rituximab Induction if cyclophosphamide unsuitable Relapses at induction or maintenance Also knocks out B cells Similar efficacy as cyclophosphamide, no fewer risks Slower onset 2 infusions at 2 week interval, then every 6-18 months Risks Infection, infusion reaction, low general antibody level, PML

17 How can we treat it? Plasma Exchange Cyclo Steroids Rituximab MMF MTX AZA

18 Mycophenolate Mofetil Induction if disease mild Maintenance if azathioprine not tolerated / effective Oral, 2-3 x day Monthly bloods Risks Infection, nausea, diarrhoea, anaemia, low WBC

19 Methotrexate Induction / maintenance Especially good for granulomatous disease ENT and lung masses in GPA Can t use for renal disease or if renal dysfunction Weekly, usually oral Monthly bloods Risks Infection, nausea, lung or liver inflammation

20 And the extras Stomach protection Infection Bone protection Blood pressure omeprazole/lansoprazole ranitidine Septrin (Pneumocystis / staph) Nystatin (fungal) Calcium/vitamin D Bisphosphonate Ramipril Amlodipine

21 Why do I feel like I do (tired)? Inflammation causes fatigue Medications can cause fatigue (steroids) Inflammation, medications and renal dysfunction cause anaemia, which causes fatigue Illness causes deconditioning

22 anaemia Will improve gradually As inflammation settles When you come off cyclophosphamide If renal function improves If left with significant renal impairment you may need Iron Erythropoietin

23 What do the blood tests mean? CRP Increases with inflammation or infection: aim <5 Haemoglobin Marker of anaemia: aim >120 WBC Avoid dropping below 4 Creatinine / egfr Marker of renal function: will find new baseline ANCA Disease activity may affect MPO or PR3 titre

24 Will it go away? You will always have the tendency to have vasculitis Relapses reported at 50% in 5 years (less now?) You may be able to come off treatment You may stay off treatment

25 Risk of relapse increased by C-ANCA ANCA positivity Rapid reduction in treatment Lack of steroid

26 What can I do to help myself? Don t worry if you don t take it all in at once You will get to know your disease Take your medication We can try and minimise side effects together Make sure you have blood tests when needed Keep up to date with vaccinations

27 What can I do to help myself? Contact GP or consultant if you are unwell Keep active, build up your fitness again Eat healthily; stick to renal dietary advice if needed Stop smoking

28 And join the West Country Vasculitis Support Group! Thank You Many thanks to Charlotte and Angie for arranging the evening

MEDICATIONS: THE GOOD, THE BAD, THE UGLY

MEDICATIONS: THE GOOD, THE BAD, THE UGLY MEDICATIONS: THE GOOD, THE BAD, THE UGLY July 13, 2013 Dr. Tanaz Kermani Assistant Clinical Professor of Medicine, Division of Rheumatology, David Geffen School of Medicine UCLA Dr. Robert Spiera Professor

More information

Tell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital

Tell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA

More information

Management of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe

Management of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe Management of Acute Vasculitis CMT teaching 3 rd June 2015 Caroline Wroe Vasculitis pub quiz Match the date with the event Dr Peter McBride, Scottish Otolaryngologist describes a disease of rapid destruction

More information

ARTHRITIS FOUNDATION VASCULITIS

ARTHRITIS FOUNDATION VASCULITIS ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 VASCULITIS This information leaflet is published by the Arthritis Foundation as part of our continuing

More information

CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation)

CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation) CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation) Participant Initials: Date of Birth: Were the following forms completed for this visit? Follow Up Form Done t Done BVASWG

More information

Recent advances in management of Pulmonary Vasculitis. Dr Nita MB

Recent advances in management of Pulmonary Vasculitis. Dr Nita MB Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction

More information

EULAR/ERA-EDTA recommendations for the management of ANCAassociated

EULAR/ERA-EDTA recommendations for the management of ANCAassociated EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis Dr. Meharunnisha Syed III year DNB Resident (General Medicine) Narayana Health-MSH Fifteen recommendations were developed,

More information

TREATMENT OF ANCA-ASSOCIATED VASCULITIS

TREATMENT OF ANCA-ASSOCIATED VASCULITIS TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,

More information

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag

More information

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Annual Rheumatology & Therapeutics Review for Organizations & Societies Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with

More information

ANCA+ VASCULITIDES CYCAZAREM,

ANCA+ VASCULITIDES CYCAZAREM, ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed

More information

Use of steroids in neurological conditions. Information for patients Pharmacy

Use of steroids in neurological conditions. Information for patients Pharmacy Use of steroids in neurological conditions Information for patients Pharmacy The information in this leaflet is about a group of medicines called steroids, which includes medicines such as prednisolone,

More information

Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card)

Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card) Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card) Exceptional healthcare, personally delivered What is Cyclophosphamide Cyclophosphamide is a potent

More information

Acute kidney injury. Information for patients Sheffield Teaching Hospitals

Acute kidney injury. Information for patients Sheffield Teaching Hospitals Acute kidney injury Information for patients Sheffield Teaching Hospitals page 2 of 12 Acute kidney injury You have been given this leaflet because you have had an episode of acute kidney injury (AKI).

More information

GRANULOMATOSIS WITH POLYANGIITIS

GRANULOMATOSIS WITH POLYANGIITIS What is granulomatosis with polyangiitis (GPA)? Granulomatosis with polyangiitis (GPA) is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict

More information

Mycophenolate (Mofetil)

Mycophenolate (Mofetil) Information about... Mycophenolate (Mofetil) Ophthalmology Service Scottish Uveitis National Managed Clinical Network What is mycophenolate? Mycophenolate (mofetil) is a drug used in the treatment of inflammatory

More information

SHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth

SHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth SHO Teaching Vasculitis Renal medicine Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth OUTLINE What is vasculitis Causes Classification Brief look into ANCA Associated Vasculitis (AAV)

More information

anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid

anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid Online publication June 24, 2009 ANCA JMAAV 1 2 ANCA JMAAV MPO-ANCA 18 17 50 J Jpn Coll Angiol, 2009, 49: 53 61 anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide,

More information

Jones slide di 23

Jones slide di 23 1 di 23 The patient with ANCA- associated vasculitis and pulmonary haemorrhage Rachel B Jones, Cambridge, UK Chairs:Hans-Joachim Anders, Munich, Germany Vladimir Tesar, Prague, Czech Republic Prof. Rachel

More information

Haemodialysis. Patient Information. Working together for better patient information. Health & care information you can trust. The Information Standard

Haemodialysis. Patient Information. Working together for better patient information. Health & care information you can trust. The Information Standard Haemodialysis Patient Information Health & care information you can trust The Information Standard Certified Member Working together for better patient information Haemodialysis (HD) helps to remove the

More information

The treatment is given every 3 weeks for 6 to 8 cycles.

The treatment is given every 3 weeks for 6 to 8 cycles. R-CVP R-CVP This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it

More information

Modified Ponticelli treatment record card

Modified Ponticelli treatment record card Modified Ponticelli treatment record card Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm

More information

DIABETES AND YOUR KIDNEYS

DIABETES AND YOUR KIDNEYS YOU AND YOUR BODY DIABETES AND YOUR KIDNEYS kk WHY IS THIS LEAFLET FOR YOU? This leaflet is about your kidneys and chronic kidney disease (CKD). This is a complication that can occur in some people with

More information

ANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic

ANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic ANCA-associated vasculitis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas,

More information

Pentostatin (Nipent )

Pentostatin (Nipent ) Pentostatin (Nipent ) Pentostatin (Nipent ) This leaflet is offered as a guide to you and your family. Your treatment will be fully explained by your doctor or nurse, who will be happy to answer any questions.

More information

Vasculitis local: systemic

Vasculitis local: systemic Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated 2- infectious

More information

RARE JUVENILE PRIMARY SYSTEMIC VASCULITIS

RARE JUVENILE PRIMARY SYSTEMIC VASCULITIS www.pediatric-rheumathology.printo.it RARE JUVENILE PRIMARY SYSTEMIC VASCULITIS WHAT IS IT? Vasculitis is an inflammation of blood vessels. Vasculitides cover a wide group of diseases. Primary vasculitis

More information

SUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF)

SUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF) SUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF) Please refer to Chester Rheumatology shared care protocol for MMF and separate responsibilities document for full details. Responsibilities

More information

Bevacizumab (Avastin ) treatment for Neurofibromatosis Type 2 (NF2) Information for patients

Bevacizumab (Avastin ) treatment for Neurofibromatosis Type 2 (NF2) Information for patients Bevacizumab (Avastin ) treatment for Neurofibromatosis Type 2 (NF2) Information for patients This booklet has been written to give you more information about bevacizumab (commonly known as Avastin). This

More information

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04 Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: AZATHIOPRINE Protocol number: CV 04 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION LIVER

More information

Plasma exchange. Information for patients Sheffield Kidney Institute (Renal Unit)

Plasma exchange. Information for patients Sheffield Kidney Institute (Renal Unit) Plasma exchange Information for patients Sheffield Kidney Institute (Renal Unit) Plasma exchange This leaflet explains about plasma exchange; the benefits, risks, alternatives and what you can expect when

More information

Azathioprine Shared Care Guideline for GPs

Azathioprine Shared Care Guideline for GPs Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis

More information

Gemcitabine and carboplatin (Breast)

Gemcitabine and carboplatin (Breast) Gemcitabine and carboplatin (Breast) Gemcitabine and carboplatin (Breast) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy

More information

Haematology. The other 2 drugs, folinic acid and GCSF, help to reduce the side effects of the treatment.

Haematology. The other 2 drugs, folinic acid and GCSF, help to reduce the side effects of the treatment. Haematology CODOX-M Chemotherapy This information is about CODOX-M chemotherapy, which is a treatment for Burkitts Lymphoma. Lymphoma is a cancer of the lymphatic system - a network of glands in the body

More information

Rituximab treatment for ANCA-associated vasculitis in childhood

Rituximab treatment for ANCA-associated vasculitis in childhood Rituximab treatment for ANCA-associated vasculitis in childhood DISCLOSURE I have no relevant financial relationships to disclose Katharine Moore MD Nov 14, 2012 University of Colorado School of Medicine

More information

The London Gastroenterology Partnership CROHN S DISEASE

The London Gastroenterology Partnership CROHN S DISEASE CROHN S DISEASE What is Crohn s disease? Crohn s disease is a condition, in which inflammation develops in parts of the gut leading to symptoms such as diarrhoea, abdominal pain and tiredness. The inflammation

More information

Myeloma Haematology and Transplant Unit

Myeloma Haematology and Transplant Unit BCD Myeloma Haematology and Transplant Unit BCD This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the

More information

Pemetrexed (Alimta ) and cisplatin

Pemetrexed (Alimta ) and cisplatin Pemetrexed (Alimta ) and cisplatin Pemetrexed (Alimta ) and cisplatin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may

More information

Medication information for patients and families

Medication information for patients and families Medication information for patients and families What is Imuran? Imuran is a medication that reduces the activity of the immune system. This type of medication is called an immunosuppressive. Imuran comes

More information

Understanding Acute Kidney Injury. Emotional and. practical support

Understanding Acute Kidney Injury. Emotional and. practical support Understanding Acute Kidney Injury Emotional and practical support This leaflet is for people who have been told that they have had Acute Kidney Injury and it s been designed to answer questions you may

More information

Protocol Version 2.0 Synopsis

Protocol Version 2.0 Synopsis Protocol Version 2.0 Synopsis Title Short Title Plasma exchange and glucocorticoid dosing in anti-neutrophil cytoplasm antibody associated vasculitis: a randomized controlled trial. PEXIVAS PEXIVAS Clinical

More information

Obinutuzumab (lymphoma) Obinutuzumab (lymphoma)

Obinutuzumab (lymphoma) Obinutuzumab (lymphoma) Obinutuzumab (lymphoma) Obinutuzumab (lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of this treatment vary: for some people, this immune therapy may reduce

More information

Vasculitis local: systemic

Vasculitis local: systemic Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated inflammation

More information

Your Chemotherapy. The Common side effects are:

Your Chemotherapy. The Common side effects are: 1 10 This information leaflet is designed to help you understand more about the treatment you have opted to undertake. You will be receiving both chemotherapy and radiotherapy that work together to treat

More information

What is this leaflet about?

What is this leaflet about? Patient Information: Medicines Medicines commonly taken by people after a transplant or with an autoimmune disease Health & care information you can trust The Information Standard Certified Member Working

More information

Package Leaflet: Information for the User

Package Leaflet: Information for the User Package Leaflet: Information for the User Imuran Tablets Azathioprine Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If you

More information

AKI Case study -Vasculitis. Sarah Mackie Renal Practice Development Nurse King s College Hospital - London

AKI Case study -Vasculitis. Sarah Mackie Renal Practice Development Nurse King s College Hospital - London AKI Case study -Vasculitis Sarah Mackie Renal Practice Development Nurse King s College Hospital - London What is vasculitis Vasculitis refers to inflammation of the blood vessels, including arteries,

More information

YOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC)

YOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC) YOUR GUIDE TO TECENTRIQ (atezolizumab) For previouslytreated advanced non-small cell lung cancer (NSCLC) ABOUT THIS BOOKLET This booklet is for people with advanced non-small cell lung cancer (NSCLC) who

More information

Management of the complications of myeloma and side-effects of treatment Christine Morris Clinical Nurse Specialist in Myeloma Royal Derby Hospital

Management of the complications of myeloma and side-effects of treatment Christine Morris Clinical Nurse Specialist in Myeloma Royal Derby Hospital Management of the complications of myeloma and side-effects of treatment Christine Morris Clinical Nurse Specialist in Myeloma Royal Derby Hospital Common problems in myeloma Myeloma-related complications/symptoms

More information

DMARDS MONITORING GUIDELINES SELKIRK MEDICAL PRACTICE

DMARDS MONITORING GUIDELINES SELKIRK MEDICAL PRACTICE DMARDS MONITORING GUIDELINES SELKIRK MEDICAL PRACTICE LIST OF DRUGS INCLUDED: ACITRETIN (Neotigason) ADALIMUMAB AMIODARONE AMISULPIRIDE ARIPRAZOLE AZATHIOPRINE CICLOSPORIN CYCLOPHOSPHAMIDE CLOZAPINE DENOSUMAB

More information

Henoch-Schӧnlein Purpura (HSP) Child Health Patient Information Leaflet

Henoch-Schӧnlein Purpura (HSP) Child Health Patient Information Leaflet Henoch-Schӧnlein Purpura (HSP) Child Health Patient Information Leaflet Henoch-Schönlein Purpura (HSP) Pronounced "hen-awk shern-line purr-purr-ah" What is Henoch-Schönlein Purpura? HSP causes blood vessels

More information

Pemetrexed (Alimta )

Pemetrexed (Alimta ) Pemetrexed (Alimta ) Pemetrexed (Alimta ) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer

More information

Cisplatin and gemcitabine (GI)

Cisplatin and gemcitabine (GI) Cisplatin and gemcitabine (GI) Cisplatin and gemcitabine (GI) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce

More information

Case Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013

Case Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013 Published online: January 27, 2013 1664 5510/13/0031 0016$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),

More information

Have a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider

Have a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider Have a healthy discussion Use this guide to start a conversation with your healthcare provider MAKE THE CONVERSATION COUNT Here are some things you may want to reflect on and discuss with your healthcare

More information

Gemcitabine and carboplatin (Lung)

Gemcitabine and carboplatin (Lung) Gemcitabine and carboplatin (Lung) Gemcitabine and carboplatin (Lung) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may

More information

Myeloma Haematology and Transplant Unit CTD1

Myeloma Haematology and Transplant Unit CTD1 CTD1 Myeloma Haematology and Transplant Unit CTD1 This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of

More information

Review Article. Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis. Milind Aurangabadkar

Review Article. Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis. Milind Aurangabadkar Review Article Vidarbha Journal of Internal Medicine Volume 23 July 207 Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis Milind Aurangabadkar ABSTRACT Anti-neutrophil

More information

Patient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet

Patient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet Page 1 of 6 Patient information sheet: BuTrans Patch This information should be read in conjunction with the Taking Opioids for pain information leaflet What type of drug is it? BuTrans transdermal patches

More information

Lupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?

Lupus. Fast facts. What is lupus? What causes lupus? Who gets lupus? Lupus Systemic lupus erythematosus, referred to as SLE or lupus, is sometimes called the "great imitator." Why? Because of its wide range of symptoms, people often confuse lupus with other health problems.

More information

NEXIUM INTRAVENOUS esomeprazole sodium

NEXIUM INTRAVENOUS esomeprazole sodium NEXIUM INTRAVENOUS esomeprazole sodium Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about NEXIUM Intravenous (IV). It does not contain

More information

GDP GDP Gemcitabine, Dexamethasone, CisPlatin Your treatment Day 1 Days 1 to 4 Day 8 dexamethasone

GDP GDP Gemcitabine, Dexamethasone, CisPlatin Your treatment Day 1 Days 1 to 4 Day 8 dexamethasone GDP GDP Gemcitabine, Dexamethasone, CisPlatin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the

More information

RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets

RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets RANITIDINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information

More information

Bendamustine. Bendamustine. Your treatment Your doctor or nurse clinician has prescribed a course of treatment with bendamustine.

Bendamustine. Bendamustine. Your treatment Your doctor or nurse clinician has prescribed a course of treatment with bendamustine. Bendamustine Bendamustine This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back,

More information

Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS

Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS Introduction: There is perhaps no rheumatic disease that evokes so much fear and confusion among both patients

More information

Haematology Mycophenolate Mofetil Information for patients

Haematology Mycophenolate Mofetil Information for patients Haematology Mycophenolate Mofetil Information for patients page 2 Why have I been prescribed this medication? You have been prescribed mycophenolate mofetil as you have immune thrombocytopenia (ITP) or

More information

Management of complications and side-effects of myeloma. Jackie Quinn Myeloma CNS Belfast Trust

Management of complications and side-effects of myeloma. Jackie Quinn Myeloma CNS Belfast Trust Management of complications and side-effects of myeloma Jackie Quinn Myeloma CNS Belfast Trust Common problems in myeloma Myeloma-related complications/symptoms Treatment-related side-effects Myeloma bone

More information

Understanding Methotrexate

Understanding Methotrexate Understanding Methotrexate Turnberg Building Inflammatory Bowel Disease Service 0161 206 4023 All Rights Reserved 2018. Document for issue as handout. What is my medication? Methotrexate is considered

More information

Gemcitabine (Gemzar )

Gemcitabine (Gemzar ) 1 Gemcitabine (Gemzar ) This fact sheet is for anyone diagnosed with pancreatic cancer who would like to find out more about gemcitabine chemotherapy to treat pancreatic cancer. It provides information

More information

TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE. Loïc Guillevin. Hôpital Cochin, Université Paris Descartes. DU MALADIES SYSTEMIQUES, 7 March 2014

TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE. Loïc Guillevin. Hôpital Cochin, Université Paris Descartes. DU MALADIES SYSTEMIQUES, 7 March 2014 TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE Loïc Guillevin Hôpital Cochin, Université Paris Descartes DU MALADIES SYSTEMIQUES, 7 March 2014 1 Disclosure of interest regarding this presentation Former

More information

Paclitaxel (Taxol) and carboplatin

Paclitaxel (Taxol) and carboplatin Paclitaxel (Taxol) and carboplatin Paclitaxel (Taxol) and carboplatin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may

More information

GCVP. Cyclophosphamide by injection Vincristine by short infusion. Gemcitabine by infusion over 30 minutes

GCVP. Cyclophosphamide by injection Vincristine by short infusion. Gemcitabine by infusion over 30 minutes GCVP GCVP This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may

More information

RAPIDLY FAILING KIDNEYS. Dr Paul Johny 2 nd yr DNB Medicine Resident

RAPIDLY FAILING KIDNEYS. Dr Paul Johny 2 nd yr DNB Medicine Resident RAPIDLY FAILING KIDNEYS Dr Paul Johny 2 nd yr DNB Medicine Resident Mr Z 67yrs old Occupation : Retired officer from electricity board Chief complaints : Fever : 5 days Right lower limb swelling and pain

More information

MACE. Etoposide via an infusion (drip) over 1 hour, once a day for 5 days

MACE. Etoposide via an infusion (drip) over 1 hour, once a day for 5 days MACE MACE This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may

More information

High dose cytarabine (Lymphoma)

High dose cytarabine (Lymphoma) High dose cytarabine High dose cytarabine (Lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk

More information

Large granular lymphocytic leukaemia (LGLL)

Large granular lymphocytic leukaemia (LGLL) Bloodwise Patient Information Large granular lymphocytic leukaemia (LGLL) For anyone affected by blood cancer Large granular lymphocytic leukaemia (LGLL) This fact sheet will help you to understand LGLL,

More information

Vascularites associées aux ANCA Traitement par le RITUXIMAB

Vascularites associées aux ANCA Traitement par le RITUXIMAB Vascularites associées aux ANCA Traitement par le RITUXIMAB Philippe Vanhille Néphrologie Médecine Interne Hôpital de Valenciennes Aix- en- Provence 2013 Cyclophosphamide therapy of severe systemic necrotizing

More information

Abemaciclib (Verzenios ) Abemaciclib (Verzenios )

Abemaciclib (Verzenios ) Abemaciclib (Verzenios ) Abemaciclib (Verzenios ) Abemaciclib (Verzenios ) Abemaciclib is a targeted (biological) therapy. This group of drugs block the growth and spread of cancer. They target and interfere with processes in

More information

PAEDIATRIC VASCULITIS

PAEDIATRIC VASCULITIS PAEDIATRIC VASCULITIS Lawrence Owino Okong o, Mmed (UoN); Mphil. (UCT). Lecturer, Department of Paediatrics and Child Health, University of Nairobi. Paediatrician/ Rheumatologist. OUTLINE Introduction

More information

NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)

NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973) NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) 467-6800 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen (973) 235-3655 Biogen Idec Contacts: Media: Christina Chan (781) 464-3260

More information

Changes in urinary metabolomic profile during relapsing renal vasculitis

Changes in urinary metabolomic profile during relapsing renal vasculitis Changes in urinary metabolomic profile during relapsing renal vasculitis Bahjat Al Ani 1,3, Martin Fitzpatrick 2, Hamad Al Nuaimi 1, Alice M Coughlan 4, Fionnuala B Hickey 4, Charles D Pusey 5, Caroline

More information

Oxford Kidney Unit. Treatment options for chronic kidney disease A brief overview

Oxford Kidney Unit. Treatment options for chronic kidney disease A brief overview Oxford Kidney Unit Treatment options for chronic kidney disease A brief overview You may feel well at the moment and may not have any symptoms from your kidney disease, but it is important that you understand

More information

Additional file 2: Details of cohort studies and randomised trials

Additional file 2: Details of cohort studies and randomised trials Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide

More information

Vincristine by short infusion Doxorubicin by injection Cyclophosphamide by injection Rituximab by an infusion over between 60 minutes to a few hours

Vincristine by short infusion Doxorubicin by injection Cyclophosphamide by injection Rituximab by an infusion over between 60 minutes to a few hours R-CHOP R-CHOP This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others

More information

Information. about cancer

Information. about cancer 1 Information about cancer This chapter may help you answer simple questions about what cancer is and how it is treated. There are more than 200 different types of cancer and a range of treatments. Being

More information

What Your Kidneys Do and What Happens When They Fail

What Your Kidneys Do and What Happens When They Fail Patient Education Chapter 2 Page 1 What Your Kidneys Do and What Happens When They Fail Objectives: 1. Understand basic kidney functions. 2. Understand symptoms of uremia and some treatments used for it.

More information

Gemcitabine and Cisplatin (urology)

Gemcitabine and Cisplatin (urology) Gemcitabine and Cisplatin Gemcitabine and Cisplatin (urology) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce

More information

Mycophenolate mofetil (MMF) for Myasthenia

Mycophenolate mofetil (MMF) for Myasthenia Neurology and Pharmacy directorate Mycophenolate mofetil (MMF) for Myasthenia Introduction This leaflet provides information on a medicine called mycophenolate mofetil (MMF) when it is used to treat myasthenia

More information

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you.

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you. New Zealand Consumer Medicine Information MABTHERA SC Rituximab 1400 mg solution for subcutaneous injection for non-hodgkin s Lymphoma and 1600mg solution for subcutaneous injection for chronic lymphocytic

More information

Pancreas transplants. What you need to know. Information for patients Sheffield Kidney Institute (Renal Unit)

Pancreas transplants. What you need to know. Information for patients Sheffield Kidney Institute (Renal Unit) Pancreas transplants What you need to know Information for patients Sheffield Kidney Institute (Renal Unit) page 2 of 16 What is the pancreas and why is it transplanted? The pancreas is part of the digestive

More information

Understanding Adalimumab

Understanding Adalimumab Understanding Adalimumab Turnberg Building Inflammatory Bowel Disease Service 0161 206 4023 All Rights Reserved 2018. Document for issue as handout. What is my treatment? Adalimumab is considered to be

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus

More information

Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura (ITP) Patient information Immune Thrombocytopenic Purpura Immune Thrombocytopenic Purpura (ITP) This leaflet is for adult patients diagnosed with Immune Thrombocytopenic Purpura also known as Immune Thrombocytopenia

More information

Traztuzumab (Herceptin)

Traztuzumab (Herceptin) Traztuzumab (Herceptin) Information for patients Chemotherapy Name Hospital No Your consultant is Important Advice Always carry your chemotherapy alert card. It is important that you know what to do if

More information

Information about... Ciclosporin. Ophthalmology Service Scottish Uveitis National Managed Clinical Network

Information about... Ciclosporin. Ophthalmology Service Scottish Uveitis National Managed Clinical Network Information about... Ciclosporin Ophthalmology Service Scottish Uveitis National Managed Clinical Network What is ciclosporin? Ciclosporin is a drug used in the treatment of inflammatory conditions and

More information

Lupus. and the Kidneys

Lupus. and the Kidneys Lupus and the Kidneys LupusuK 2015 This information booklet has been produced by LUPUS UK 2015 LUPUS UK LUPUS UK is the national charity caring for those with systemic lupus erythematosus (SLE) and discoid

More information

Cisplatin and Capecitabine

Cisplatin and Capecitabine Cisplatin and Capecitabine Cisplatin and Capecitabine This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk

More information

ANCA-associated systemic vasculitis (AASV)

ANCA-associated systemic vasculitis (AASV) PAPER 2007 Royal College of Physicians of Edinburgh ANCA-associated systemic vasculitis (AASV) 1 DC Kluth, 2 J Hughes 1 Reader in Nephrology, MRC Centre for Inflammation Research, University of Edinburgh,

More information

Vinblastine (Lymphoma)

Vinblastine (Lymphoma) Vinblastine (Lymphoma) Vinblastine (Lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the

More information